当前位置: X-MOL 学术Am. J. Respir. Cell Mol. Biol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
PR1P Stabilizes VEGF and Upregulates its Signaling to Reduce Elastase Induced Murine Emphysema.
American Journal of Respiratory Cell and Molecular Biology ( IF 5.9 ) Pub Date : 2020-10-01 , DOI: 10.1165/rcmb.2019-0434oc
Avner Adini 1, 2, 3, 4 , Hao Wu 1, 2, 3 , Duy T Dao 1, 3 , Victoria H Ko 1, 3 , Lumeng J Yu 1, 3 , Amy Pan 1, 3 , Mark Puder 1, 3 , Selome Z Mitiku 1, 2, 3, 4 , Ratnakar Potla 1, 2, 3 , Hong Chen 1, 2, 3 , James M Rice 1, 2, 3 , Benjamin D Matthews 1, 2, 3, 4
Affiliation  

Emphysema is a progressive and fatal lung disease with no cure that is characterized by thinning, enlargement, and destruction of alveoli, leading to impaired gas exchange. Disease progression is due in part to dysregulation of VEGF (vascular endothelial growth factor) signaling in the lungs and increased lung-cell apoptosis. Here we asked whether PR1P (Prominin-1–derived peptide), a novel short peptide we designed that increases VEGF binding to endothelial cells, could be used to improve outcome in in vitro and in vivo models of emphysema. We used computer simulation and in vitro and in vivo studies to show that PR1P upregulated endogenous VEGF receptor-2 signaling by binding VEGF and preventing its proteolytic degradation. In so doing, PR1P mitigated toxin-induced lung-cell apoptosis, including from cigarette-smoke extract in vitro and from LPS in vivo in mice. Remarkably, inhaled PR1P led to significantly increased VEGF concentrations in murine lungs within 30 minutes that remained greater than twofold above that of control animals 24 hours later. Finally, inhaled PR1P reduced acute lung injury in 4- and 21-day elastase-induced murine emphysema models. Taken together, these results highlight the potential of PR1P as a novel therapeutic agent for the treatment of emphysema or other lung diseases characterized by VEGF signaling dysregulation.



中文翻译:

PR1P 稳定 VEGF 并上调其信号以减少弹性蛋白酶诱导的鼠肺气肿。

肺气肿是一种进行性和致命的肺部疾病,无法治愈,其特征是肺泡变薄、扩大和破坏,导致气体交换受损。疾病进展部分归因于肺中 VEGF(血管内皮生长因子)信号传导的失调和肺细胞凋亡增加。在这里,我们询问 PR1P(Prominin-1 衍生肽),一种我们设计的增加 VEGF 与内皮细胞结合的新型短肽,是否可用于改善体外体内肺气肿模型的结果。我们使用计算机模拟和体外体内研究表明,PR1P 通过结合 VEGF 并阻止其蛋白水解降解上调内源性 VEGF 受体 2 信号传导。通过这样做,PR1P 减轻了毒素诱导的肺细胞凋亡,包括体外的香烟烟雾提取物和小鼠体内的LPS 。值得注意的是,吸入 PR1P 在 30 分钟内导致鼠肺中 VEGF 浓度显着增加,24 小时后仍比对照动物高出两倍以上。最后,吸入 PR1P 可减少 4 天和 21 天弹性蛋白酶诱导的小鼠肺气肿模型中的急性肺损伤。总之,这些结果突出了 PR1P 作为治疗肺气肿或其他以 VEGF 信号失调为特征的肺部疾病的新型治疗剂的潜力。

更新日期:2020-10-02
down
wechat
bug